Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ready Or Not: FDA Accepting Adaptive Trial Applications

Executive Summary

One of the biggest adaptive trial issues yet to be hammered out between FDA and industry is who will have access to unblinded clinical trial data and what that structure would look like, according to FDA officials

You may also be interested in...



Late-Stage Trials Pose Challenge As FDA Molds Adaptive Design Guidance

The work group developing FDA's guidance on adaptive clinical trial design is still trying to figure out the complex issues associated with late-stage studies, the Center for Drug Evaluation and Research's "town hall" discussion at the Drug Information Association annual meeting in Atlanta revealed

Late-Stage Trials Pose Challenge As FDA Molds Adaptive Design Guidance

The work group developing FDA's guidance on adaptive clinical trial design is still trying to figure out the complex issues associated with late-stage studies, the Center for Drug Evaluation and Research's "town hall" discussion at the Drug Information Association annual meeting in Atlanta revealed

Industry Encouraged To Spread Its Wings In Learn Phase of Adaptive Trials

While FDA is granting industry a great deal of leeway in designing early, learn-phase adaptive trial models, the agency is suggesting that emphasis be placed on dose response and exposure risk, FDA officials indicated at a recent Pharmaceutical Research & Manufacturers of America workshop

Related Content

UsernamePublicRestriction

Register

OM013164

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel